SCHEMBL10322064

SCHEMBL10322064

COC(=O)c1ccc(C)c(NC(=O)c2cc3ccc(N4CCN(C)CC4)nc3[nH]c2=O)c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.61
▸ DYRK1B Q9Y463 3/20 0.61
▸ WDR5 P61964 5/20 0.47
▸ KMT2A Q03164 2/20 0.44
▸ RBBP5 Q15291 1/20 0.44
▸ ASH2L Q9UBL3 1/20 0.44
▸ TSHR P16473 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10322092 0.90 DYRK1A (0.61) DYRK1ADYRK1BWDR5KMT2ARBBP5
SCHEMBL10322440 0.85 DYRK1A (0.61) DYRK1ADYRK1BWDR5KMT2ARBBP5
SCHEMBL10323421 0.85 POLB (0.48) DYRK1ADYRK1BWDR5KMT2ATSHR
SCHEMBL10320554 0.82 KDM4E (0.51) KMT2ATSHRKDM4EALDH1A1GAA
SCHEMBL10322269 0.81 DYRK1A (0.72) DYRK1ADYRK1BTSHRALDH1A1MAPK14
SCHEMBL10323269 0.77 DYRK1A (0.69) DYRK1ADYRK1BWDR5
SCHEMBL10323825 0.77 DYRK1A (0.68) DYRK1ADYRK1BKMT2ABRAF
SCHEMBL10322786 0.76 KDM4E (0.45) KMT2AKDM4EALDH1A1AURKA
SCHEMBL10322753 0.76 DYRK1A (0.61) DYRK1ADYRK1BWDR5TSHRALDH1A1
SCHEMBL10324364 0.76 DYRK1A (1.00) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO claimed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US claimed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 DYRK1A 1366/4885DYRK1B 2109/4885WDR5 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback